Davis's Drug Guide
nirsevimab
General
Pronunciation:
nir-sev-i-mab
Trade Name(s)
- Beyfortus
Ther. Class.
Pharm. Class.
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Nirsevimab." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580070/all/nirsevimab.
Vallerand AHA, Sanoski CAC, . Nirsevimab. Davis's Drug Guide. F.A. Davis Company; 2025. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580070/all/nirsevimab. Accessed April 16, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Nirsevimab. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580070/all/nirsevimab
Vallerand AHA, Sanoski CAC, . Nirsevimab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 April 16]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580070/all/nirsevimab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - nirsevimab
ID - 3580070
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580070/all/nirsevimab
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
